X
KRYS icon

Xponance’s Krystal Biotech KRYS Stock Holding History

Xponance’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$937K Buy
2,522
+183
+8% +$54.7K 0.01% 815
2026
Q1 		$604K Buy
2,339
+380
+19% +$101K ﹤0.01% 935
2025
Q4 		$483K Buy
1,959
+8
+0.4% +$1.68K ﹤0.01% 966
2025
Q3 		$344K Buy
1,951
+22
+1% +$3.29K ﹤0.01% 1098
2025
Q2 		$265K Buy
1,929
+56
+3% +$8.22K ﹤0.01% 1190
2025
Q1 		$338K Buy
1,873
+88
+5% +$14.8K ﹤0.01% 1058
2024
Q4 		$280K Buy
1,785
+155
+10% +$27.5K ﹤0.01% 1149
2024
Q3 		$297K Buy
1,630
+53
+3% +$10.2K ﹤0.01% 1095
2024
Q2 		$290K Buy
1,577
+265
+20% +$44.5K ﹤0.01% 1068
2024
Q1 		$233K Buy
+1,312
New +$182K ﹤0.01% 1136

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Xponance's KRYS Position: Q2 2026 in Review

Xponance increased its Krystal Biotech (KRYS) stake by 7.8% in Q2 2026, buying an estimated $54.7K and bringing the position to 2,522 shares worth $937K. The position accounts for 0.01% of the portfolio, ranked #815.

Xponance first reported a position in KRYS in Q1 2024 and has held it in 10 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Xponance held 2,522 shares of Krystal Biotech worth $937K as of Q2 2026.
  • Xponance bought 183 Krystal Biotech shares in Q2 2026, an estimated $54.7K.
  • Krystal Biotech made up 0.01% of Xponance's portfolio in Q2 2026, its #815 holding.
  • Xponance first reported a position in Krystal Biotech in Q1 2024 and has held it in 10 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.